JP5231490B2 - 慢性疲労症候群の治療用の医薬の製造のための、アルファ−１−アンチトリプシンの使用 - Google Patents

慢性疲労症候群の治療用の医薬の製造のための、アルファ−１−アンチトリプシンの使用 Download PDF

Info

Publication number
JP5231490B2
JP5231490B2 JP2010147994A JP2010147994A JP5231490B2 JP 5231490 B2 JP5231490 B2 JP 5231490B2 JP 2010147994 A JP2010147994 A JP 2010147994A JP 2010147994 A JP2010147994 A JP 2010147994A JP 5231490 B2 JP5231490 B2 JP 5231490B2
Authority
JP
Japan
Prior art keywords
aat
cfs
alpha
treatment
antitrypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010147994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011012060A (ja
JP2011012060A5 (https=
Inventor
ガルシア クインターナ アナ
アレグレ マーティン ホセ
Original Assignee
グリフォルス，ソシエダッド アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリフォルス，ソシエダッド アノニマ filed Critical グリフォルス，ソシエダッド アノニマ
Publication of JP2011012060A publication Critical patent/JP2011012060A/ja
Publication of JP2011012060A5 publication Critical patent/JP2011012060A5/ja
Application granted granted Critical
Publication of JP5231490B2 publication Critical patent/JP5231490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2010147994A 2009-06-30 2010-06-29 慢性疲労症候群の治療用の医薬の製造のための、アルファ−１−アンチトリプシンの使用 Active JP5231490B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930387 2009-06-30
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (3)

Publication Number Publication Date
JP2011012060A JP2011012060A (ja) 2011-01-20
JP2011012060A5 JP2011012060A5 (https=) 2011-03-31
JP5231490B2 true JP5231490B2 (ja) 2013-07-10

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010147994A Active JP5231490B2 (ja) 2009-06-30 2010-06-29 慢性疲労症候群の治療用の医薬の製造のための、アルファ−１−アンチトリプシンの使用

Country Status (16)

Country Link
US (1) US9205134B2 (https=)
EP (1) EP2289540B1 (https=)
JP (1) JP5231490B2 (https=)
CN (1) CN101934071B (https=)
AR (1) AR077123A1 (https=)
AU (1) AU2010202203B2 (https=)
BR (1) BRPI1002087B1 (https=)
CA (1) CA2706212C (https=)
CL (1) CL2010000575A1 (https=)
ES (2) ES2332645B1 (https=)
MX (1) MX2010006125A (https=)
NZ (1) NZ585890A (https=)
PL (1) PL2289540T3 (https=)
PT (1) PT2289540E (https=)
RU (1) RU2436590C1 (https=)
UY (1) UY32670A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014751A8 (pt) * 2011-12-19 2017-07-04 Lfb Usa Inc composição compreendendo alfa-1-antitripsina, células epiteliais de glândula mamária, mamífero não humano transgênico, e, método para reduzir a atividade de elastase no pulmão
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2001081343A2 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2002006837A1 (en) * 2000-07-14 2002-01-24 Matsushita Electric Industrial Co., Ltd. Particle-labeled protein and immuno-chromatograph using the same
AU2003286258B2 (en) 2002-11-20 2006-12-21 Arriva-Prometic Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US7344882B2 (en) * 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2006026837A1 (en) * 2004-09-07 2006-03-16 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
MX2010003113A (es) * 2007-09-25 2010-04-01 Abbott Lab Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
HUE030205T2 (en) 2007-11-02 2017-05-29 Grifols Therapeutics Inc A method, composition, and product for providing alpha-1-antitrypsin

Also Published As

Publication number Publication date
NZ585890A (en) 2011-11-25
AR077123A1 (es) 2011-08-03
AU2010202203A1 (en) 2011-01-20
CL2010000575A1 (es) 2011-10-28
US9205134B2 (en) 2015-12-08
US20100331261A1 (en) 2010-12-30
CA2706212C (en) 2014-02-04
BRPI1002087A2 (pt) 2012-03-13
EP2289540B1 (en) 2012-08-22
AU2010202203B2 (en) 2012-08-23
EP2289540A1 (en) 2011-03-02
MX2010006125A (es) 2011-01-05
ES2332645B1 (es) 2010-10-18
PL2289540T3 (pl) 2013-03-29
ES2392691T3 (es) 2012-12-12
CN101934071B (zh) 2012-11-28
CN101934071A (zh) 2011-01-05
JP2011012060A (ja) 2011-01-20
UY32670A (es) 2011-01-31
BRPI1002087B1 (pt) 2019-07-02
CA2706212A1 (en) 2010-12-30
RU2436590C1 (ru) 2011-12-20
HK1148198A1 (en) 2011-09-02
PT2289540E (pt) 2012-12-04
ES2332645A1 (es) 2010-02-09

Similar Documents

Publication Publication Date Title
JP5231490B2 (ja) 慢性疲労症候群の治療用の医薬の製造のための、アルファ−１−アンチトリプシンの使用
CN1711101A (zh) 孤独症及相似障碍的治疗
EP3518948B1 (en) Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
KR101401744B1 (ko) Ｎ-아세틸-ｌ-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물
CN103649106B (zh) 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合
Nagel et al. Varicella zoster virus infections
JPS6237615B2 (https=)
KR102725812B1 (ko) 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 치료용 약학조성물
JP4351663B2 (ja) 繊維筋症治療用薬物を調製するためのα−１抗トリプシンの使用
HK1148198B (en) Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome
RU2188665C1 (ru) Противовирусное и антибактериальное средство "интерлизин"
US20230277650A1 (en) Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv)
EP4197547A1 (en) Composition for treating or preventing vasculitis and diseases associated with vasculitis
HK1083601B (en) Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia
KR20170041116A (ko) 신경계의 보호 및/또는 복구용 조성물 및 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130321

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160329

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5231490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250